ClinicalTrials.gg
CompletedNCT05522816Updated Jul 2, 2025

KX01 Ointment Phase 1 Study in Patients With Plaque Type Psoriasis

A Phase 1 interventional study of KX01 0.01% (0.1 mg/g) and Placebo in Psoriasis, sponsored by PharmaEssentia. Completed. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2025-07-02.

Sponsored by PharmaEssentia · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 6 years 9 months after the study started (first participant enrolled Oct 2015, registered Aug 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Study summary

This is a Phase I dose escalation study to assess the safety, tolerability and activity of three different strengths of topical KX01 in the treatment of patients with plaque-type psoriasis.

Read the detailed description

This is a Phase I dose escalation study to assess the safety, tolerability and activity of three different strengths of topical KX01 (Tirbanibulin Ointment) in the treatment of patients with plaque-type psoriasis. The study will be performed in four stages as below.

Stage I: 6 patients (KX01 0.01% [0.1 mg/g]) + 2 patients (placebo); Stage II: 6 patients (KX01 0.1% [1.0 mg/g] + 2 patients (placebo); Stage III: 6 patients (KX01 1% [10 mg/g]) for 5 days; Stage IV: 6 patients (KX01 1% [10 mg/g]), duration escalation for up to 4 cycles.

If there's no major safety concern in the previous stage with an unanimous consent by the sponsor and the principle investigator, the study proceeded to the next stage.

The primary objective is to evaluate the safety and tolerability of three different strengths of KX01 ointment in patients with plaque-type psoriasis. The secondary objective is to gain evidence regarding the activity of three different strengths of KX01 ointment in patients with plaque-type psoriasis.

02

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • KX01
  • Ointment
  • Psoriasis
  • Phase I
  • Clinical trial
03

In context

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

This study's enrollment of 28 is below the median of 75 across 1,567 interventional studies indexed under Psoriasis.

Browse Psoriasis studies →

Lead sponsor

PharmaEssentia is the lead sponsor of 17 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients with plaque-type psoriasis, 20 years and older.
  • Patient has a confirmed diagnosis of chronic plaque-type psoriasis for at least six months. For stage 4, PGA should be ≧3 \&≦5 at baseline.
  • A single lesion of ≥ 16 square centimetre and ≤ 625 square centimetre in size for Stage 1 and 2, and ≥ 16 square centimetre and ≤ 100 square centimetre in size for Stage 3 and 4 are selected as the target lesion (assessed at screening and Day 1).
  • Medical history, vital signs, physical examination, standard 12-lead and laboratory investigations have to be clinically insignificant or within laboratory reference ranges for the relevant laboratory tests, unless the investigator consider the deviation for out of range values to be irrelevant for the purpose of the study.
  • No other disorders that, in the investigator's opinion, will prevent the patient from safely participating in this study or interfere with the evaluation of the patient's psoriasis.
  • Patient is able to discontinue the use of any systemic medication or therapy for psoriasis.
  • For females, either of the following conditions will be met: 1. Not of : Surgically sterilized, undergone a hysterectomy, amenorrhea for ≥ 12 months and considered ; 2. Of childbearing potential: Negative serum pregnancy test at screening and not lactating, Either abstaining from sexual activity, or have to agree to use an accepted method of , and agree to continue with the same method throughout the study.
  • Male patients with partners of childbearing potential have to be willing to use contraception during the study and three months after end of treatment and is not to donate sperm for the duration of the study and for 3 months thereafter.
  • Patient have to be able to provide written prior to the initiation of any study related procedures and able to comply with all the requirements of the study.

Exclusion criteria

Exclusion Criteria:

  • History of to the medicinal product (IMP) or to medicinal products with similar chemical structures.
  • Presence of a skin disorder other than psoriasis in the target areas to be evaluated, including forms of inflammatory or non-inflammatory skin disorders that might interfere with determining efficacy or tolerability of the IMP.
  • Severe forms of psoriasis or forms of psoriasis other than plaque psoriasis.
  • All systemic psoriasis medications, including psoralens and ultraviolet A radiation treatments or other systemic medication, are not allowed within five half-lives or 4 weeks (whichever is longer) prior to the first administration of the IMP.
  • The use of topical therapies for psoriasis, including ultraviolet light B, on the target lesion to be studied within two weeks prior to the first administration of the IMP.
  • Previous treatment with anti-tumor necrosis factor/interleukin (IL)-12/IL-23 or any other monoclonal antibodies within three months prior to the first administration of the IMP.
  • Presence or history of any acute or chronic disease which could interfere with the patient's participation or study outcome and at discretion of the clinical investigator.
  • Patient with drug-induced psoriasis and is unable to discontinue the causal agent(s).
  • Patient using prescription or non-prescription systemic drugs (e.g. vitamins and dietary, herbal supplements, paracetamol, aspirin or non-steroidal anti-inflammatory drugs [NSAIDs]) that might have an effect on psoriasis and is unable to maintain the stable dose or discontinue the dose during the study period.
  • Participation in another study with an experimental drug, where the last administration of the previous IMP is within 4 weeks (or within five elimination half-lives for chemical entities or two elimination half-lives for antibodies or insulin, whichever is longer) before administration of IMP in this study, at the discretion of the investigator.
  • A positive serum pregnancy test (beta human chorionic gonadotropin) or lactation.
  • Vulnerable patients, e.g. persons in detention.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    KX01 0.01% in stage I

    Six patients in the stage 1 will receive KX01 0.01% (0.1 mg/g) for 2 weeks, followed by 1-week wash-out, another 2-week treatment, and then 2-week follow-up.

    Drug: KX01 0.01% (0.1 mg/g)

  • Placebo comparator
    Placebo in stage 1

    Two patients in the stage 1 will receive placebo treatment for 2 weeks, followed by 1-week wash-out, another 2-week treatment, and then 2-week follow-up.

    Drug: Placebo

  • Experimental
    KX01 0.1% in stage 2

    Six patients in the stage 2 will receive KX01 0.1% (1.0 mg/g) for 4 weeks, followed by 2-week follow-up.

    Drug: KX01 0.1% (1.0 mg/g)

  • Placebo comparator
    Placebo in stage 2

    Two patients in the stage 2 will receive placebo treatment for 4 weeks, followed by 2-week follow-up.

    Drug: Placebo

  • Experimental
    KX01 1% for 5 days in stage 3

    Six patients in stage 3 will receive 1% KX01 (10 mg/g) once daily for consecutive 5 days and then receive post-treatment follow-up on Day 6, 15 and 29.

    Drug: KX01 1% (10 mg/g) for 5 days

  • Experimental
    KX01 1% for consecutive 5 days and 2 days rest for 1 cycle, and repeat up to 4 cycles in stage 4

    Six patients in stage 4 will be treated with daily KX01 1% (10 mg/g) ointment for consecutive 5 days and 2 days rest for 1 cycle, and repeat up to 4 cycles. And post-treatment follow-up visits will be conducted 14 days (Follow-up visit 1) and 28 days (Follow-up visit 2) after the end of cycle 4 treatment.

    Drug: KX01 1% (10 mg/g) for consecutive 5 days and 2 days rest for 1 cycle, and repeat up to 4 cycles

Interventions

  • DrugKX01 0.01% (0.1 mg/g)

    Drug page: Tirbanibulin

    Stage 1: 6 patients (KX01 0.01% \[0.1 mg/g\])

  • DrugPlacebo

    Contains same excipients with KX01 but do not contain Tirbanibulin

  • DrugKX01 0.1% (1.0 mg/g)

    Drug page: Tirbanibulin

    Stage 2: 6 patients (KX01 0.1% \[1.0 mg/g\])

  • DrugKX01 1% (10 mg/g) for 5 days

    Drug page: Tirbanibulin

    Stage 3: 6 patients (KX01 1% \[10 mg/g\]) for 5 days

  • DrugKX01 1% (10 mg/g) for consecutive 5 days and 2 days rest for 1 cycle, and repeat up to 4 cycles

    Drug page: Tirbanibulin

    Stage 4: 6 patients (KX01 1% \[10 mg/g\])for consecutive 5 days and 2 days rest for 1 cycle, and repeat up to 4 cycles

06

What researchers measure

Primary outcomes

  1. Adverse event at Stage 1

    Incidence of adverse event

    Time frame: Day 50

  2. Adverse event at Stage 2

    Incidence of adverse event

    Time frame: Day 43

  3. Adverse event at Stage 3

    Incidence of adverse event

    Time frame: Day 29

  4. Adverse event at Stage 4

    Incidence of adverse event

    Time frame: 28 days after the end of cycle 4 treatment (each cycle is 7 days)

  5. Local tolerability score at Stage 1

    4-point (0-3) rating scale; higher scores mean a worse outcome

    Time frame: Day 50

  6. Local tolerability score at Stage 2

    4-point (0-3) rating scale; higher scores mean a worse outcome

    Time frame: Day 43

  7. Local tolerability score at Stage 3

    4-point (0-3) rating scale; higher scores mean a worse outcome

    Time frame: Day 29

  8. Local tolerability score at Stage 4

    4-point (0-3) rating scale; higher scores mean a worse outcome

    Time frame: 28 days after the end of cycle 4 treatment (each cycle is 7 days)

  9. Vital signs at Stage 1

    any abnormal vital sign with clinical significance

    Time frame: Day 50

  10. Vital signs at Stage 2

    any abnormal vital sign with clinical significance

    Time frame: Day 43

  11. Vital signs at Stage 3

    any abnormal vital sign with clinical significance

    Time frame: Day 29

  12. Vital signs at Stage 4

    any abnormal vital sign with clinical significance

    Time frame: 28 days after the end of cycle 4 treatment (each cycle is 7 days)

  13. 12-lead ECG at Stage 1

    any abnormal finding of 12-lead ECG with clinical significance

    Time frame: Day 36

  14. 12-lead ECG at Stage 2

    any abnormal finding of 12-lead ECG with clinical significance

    Time frame: Day 29

  15. 12-lead ECG at Stage 3

    any abnormal finding of 12-lead ECG with clinical significance

    Time frame: Day 29

  16. 12-lead ECG at Stage 4

    any abnormal finding of 12-lead ECG with clinical significance

    Time frame: 28 days after the end of cycle 4 treatment (each cycle is 7 days)

  17. Hematology assessments at Stage 1

    any abnormal hematologic lab data with clinical significance

    Time frame: Day 36

  18. Clinical chemistry assessments at Stage 1

    any abnormal chemical lab data with clinical significance

    Time frame: Day 36

  19. Urinalysis assessments at Stage 1

    any abnormal urine lab data with clinically significant

    Time frame: Day 36

  20. Hematology assessments at Stage 2

    any abnormal hematologic lab data with clinical significance

    Time frame: Day 29

  21. Clinical chemistry assessments at Stage 2

    any abnormal chemical lab data with clinical significanc

    Time frame: Day 29

  22. Urinalysis assessments at Stage 2

    any abnormal urine lab data with clinically significant

    Time frame: Day 29

  23. Hematology assessments at Stage 3

    any abnormal hematologic lab data with clinical significance

    Time frame: Day 29

  24. Clinical chemistry assessments at Stage 3

    any abnormal chemical lab data with clinical significanc

    Time frame: Day 29

  25. Urinalysis assessments at Stage 3

    any abnormal urine lab data with clinically significant

    Time frame: Day 29

  26. Hematology assessments at Stage 4

    any abnormal hematologic lab data with clinical significance

    Time frame: 28 days after the end of cycle 4 treatment (each cycle is 7 days)

  27. Clinical chemistry assessments at Stage 4

    any abnormal chemical lab data with clinical significanc

    Time frame: 28 days after the end of cycle 4 treatment (each cycle is 7 days)

  28. Urinalysis assessments at Stage 4

    any abnormal urine lab data with clinically significant

    Time frame: 28 days after the end of cycle 4 treatment (each cycle is 7 days)

Secondary outcomes

  1. Change between baseline and end of treatment in target area score (TAS) at Stage 1

    Change between baseline and end of treatment in TAS that evaluates the target lesion's erythema (0-4), plaque elevation (0-4) and scaling (0-4) on a five-point scale for each item (higher scores mean a worse outcome)

    Time frame: Stage 1: Up to Day 36

  2. Change between baseline and end of TAS at Stage 2

    Change between baseline and end of treatment in TAS that evaluates the target lesion's erythema (0-4), plaque elevation (0-4) and scaling (0-4) on a five-point scale for each item

    Time frame: Up to Day 29

  3. Change between baseline and end of TAS at Stage 3

    Change between baseline and end of treatment in TAS that evaluates the target lesion's erythema (0-4), plaque elevation (0-4) and scaling (0-4) on a five-point scale for each item

    Time frame: Up to Day 6

  4. Change between baseline and end of TAS at Stage 4

    Change between baseline and end of treatment in TAS that evaluates the target lesion's erythema (0-4), plaque elevation (0-4) and scaling (0-4) on a five-point scale for each item

    Time frame: Up to the end of cycle 4 treatment (each cycle is 7 days)

  5. TAS 50 at Stage 1

    ≧50% reduction in TAS score from baseline at the end of treatment

    Time frame: Up to Day 36

  6. TAS 50 at Stage 2

    ≧50% reduction in TAS score from baseline at the end of treatment

    Time frame: Up to Day 29

  7. TAS 50 at Stage 3

    ≧50% reduction in TAS score from baseline at the end of treatment

    Time frame: Up to Day 6

  8. TAS 50 at Stage 4

    ≧50% reduction in TAS score from baseline at the end of treatment

    Time frame: Up to the end of cycle 4 treatment (each cycle is 7 days)

  9. Physician global assessment (PGA) score of the target lesion at the end of treatment of Stage 1

    Achieving a score of "clear" (grade 0) or "almost clear" (grade 1) and at least 2 grade improvement from the baseline score in a 7-point score (0-6, higher scores mean a worse outcome).

    Time frame: Up to Day 36

  10. PGA score of the target lesion at the end of treatment of Stage 2

    Achieving a score of "clear" (grade 0) or "almost clear" (grade 1) and at least 2 grade improvement from the baseline score in a 7-point score

    Time frame: Up to Day 29

  11. PGA score of the target lesion at the end of treatment of Stage 3

    Achieving a score of "clear" (grade 0) or "almost clear" (grade 1) and at least 2 grade improvement from the baseline score in a 7-point score

    Time frame: Up to Day 6

  12. PGA score of the target lesion at the end of treatment of Stage 4

    Achieving a score of "clear" (grade 0) or "almost clear" (grade 1) and at least 2 grade improvement from the baseline score in a 7-point score

    Time frame: Up to the end of cycle 4 treatment (each cycle is 7 days)

  13. Disease relapse at Stage 2

    Relapse is the loss of more than 50% of TAS improvement from baseline in patients who achieve a clinically meaningful response. Clinical meaningful response is defined as a reduction of ≥50% in TAS from baseline during the treatment.

    Time frame: Day 43

  14. Disease relapse at Stage 3

    Relapse is the loss of more than 50% of TAS improvement from baseline in patients who achieve a clinically meaningful response. Clinical meaningful response is defined as a reduction of ≥50% in TAS from baseline during the treatment.

    Time frame: Day 15 and Day 29

  15. Disease relapse at Stage 4

    Relapse is the loss of more than 50% of TAS improvement from baseline in patients who achieve a clinically meaningful response. Clinical meaningful response is defined as a reduction of ≥50% in TAS from baseline during the treatment.

    Time frame: 14 days after cycle 4 treatment and 28 days after cycle 4 treatment (each cycle is 7 days)

  16. Plasma KX01 concentrations (ng/ml) at Stage 1

    Detection of plasma KX01 concentrations (ng/ml)

    Time frame: Up to Day 36

  17. Plasma KX01 concentrations (ng/ml) at Stage 2

    Detection of plasma KX01 concentrations (ng/ml)

    Time frame: Up to Day 29

  18. Plasma KX01 concentrations (ng/ml) at Stage 3

    Detection of plasma KX01 concentrations (ng/ml)

    Time frame: Up to Day 15

  19. Plasma KX01 concentrations (ng/ml) at Stage 4

    Detection of plasma KX01 concentrations (ng/ml)

    Time frame: 14 days after cycle 4 treatment (each cycle is 7 days)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2015 to primary completion in Mar 2021, 64 months.

Of 137 industry-sponsored phase 1 interventional studies under Psoriasis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 64 months is above that.

Counting every sponsor, half of 155 studies reached it within 10 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2022
First posted
Aug 31, 2022
StartActual
Oct 27, 2015
Primary completionActual
Mar 10, 2021
CompletionActual
Mar 10, 2021
Last update
Jul 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05522816
Lead sponsor
PharmaEssentia
Responsible party
Sponsor
First posted
Aug 31, 2022
Start date
Oct 27, 2015
Primary completion
Mar 10, 2021
Completion
Mar 10, 2021
Last update
Jul 2, 2025

Study contacts

Jin-Bon Hong, M.D.
principal investigator · Department of Dermatology, National Taiwan University Hospital, Taipei, Taiwan
Po-Yuan Wu, M.D., Ph.D.
principal investigator · Department of Dermatology, China Medical University Hospital, Taichung, Taiwan

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirbanibulin

Start the discussion